The granting of a patent in Japan for a treatment related to inflammatory conditions is a significant development for GRI Bio. It enhances the company's intellectual property portfolio, which is crucial for protecting its innovations and maintaining a competitive edge. This patent could also facilitate entry into the Japanese market, potentially increasing revenue streams and market presence. The news is likely to have a positive short-term impact on GRI Bio's stock price as investors may anticipate future growth opportunities.